search

Active clinical trials for "Peanut Hypersensitivity"

Results 91-100 of 126

Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy

Peanut Allergy

This study will assess the clinical potency of several exposure levels of QGE031 in decreasing the sensitivity against peanut allergen.

Withdrawn9 enrollment criteria

Walnut Oral Immunotherapy for Tree Nut Allergy

Peanut Allergy

The purpose of this research study is to learn about the medical effects, safety, and how the Walnut Oral Immunotherapy (OIT) treatment affects your body (immune system). This type of immunotherapy involves giving increasing doses of walnut allergen to gradually build up a person's tolerance to walnut and at least one other tree nut. The goal of the study is to determine whether participants can tolerate (eat) walnuts and at least one other tree nut in their diet after stopping the study therapy.

Withdrawn23 enrollment criteria

Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

Food Allergy Peanut

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.

Withdrawn4 enrollment criteria

Tolerance Following Peanut Oral Immunotherapy

Peanut Allergy

The unifying objective of this project is to determine whether peanut oral immunotherapy (PN OIT) induced clinical tolerance in the context of food allergy is significantly associated with the expansion of a specific regulatory T cell subset (CD45RA- CD25++ FoxP3++) that is thought to be inducible in the gut-associated lymphoid compartment and associated with immunological tolerance. The hypothesis of the study is that the induction of Treg cells will be associated with clinical tolerance. The investigators will measure the change from baseline of induced Treg cells as a frequency of total CD4 T cells during active treatment and compare that between participants who achieve significant clinical tolerance (Tolerance and Partial Tolerance Groups as defined below) and those who do not (Treatment Failure Group).

Completed17 enrollment criteria

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut...

Peanut Allergy

The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.

Completed12 enrollment criteria

Allergy Experience Study

Peanut Allergy

People who are undergoing oral immunotherapy for food allergy treatment can feel anxious about the treatment process, particularly when they have allergic responses (e.g., hives, vomiting, nausea) during the dosing process. People may commonly believe that these symptoms are simply side effects that must be endured or avoided. However, the investigators propose that changing participants' mindsets about the meaning of symptoms-toward viewing them as a sign that the treatment is working and desensitization is increasing-during the treatment process will reduce anxiety and improve treatment outcomes.

Completed9 enrollment criteria

The Grown Up Peanut Immunotherapy Study

Peanut Allergy

To determine efficacy and safety of peanut oral immunotherapy in adults with peanut allergy.

Unknown status41 enrollment criteria

Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy

Peanut Allergy

Severe peanut allergy is different from other allergic reactions because it can lead to fatal reactions and is an invisible disability. There is no cure today. The purpose of this study is to treat children and adolescents with severe peanut allergy with oral immunotherapy with peanuts under the protection of anti-IgE (immunoglobulin E) antibodies (omalizumab), and thereby inducing tolerance to peanuts. The treatment will be monitored by basophil cell stimulation (CD-sens).

Unknown status10 enrollment criteria

Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization...

Peanut Allergies in Children

The primary objective of this study is to evaluate, compared to non-treatment, the impact of a titrated dose (1 mg once a day, then 1 mg twice a day and finally a full 2 mg twice a day) of ketotifen on the adverse event profile emerging from a rapid peanut desensitization protocol, in children with established peanut allergy.

Unknown status14 enrollment criteria

High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety

Peanut Allergy

In this trial the investigators aim to assess the effectiveness and safety of oral immunotherapy with peanut protein in high and low dose (300mg versus 150mg) in children with peanuts allergy.

Unknown status23 enrollment criteria
1...91011...13

Need Help? Contact our team!


We'll reach out to this number within 24 hrs